Why the study?
Does aspirin associated with phosphatidylcholine (PL2200) reduce GI ulcerations compared to standard low-dose aspirin in patients requiring LDA therapy?
Does aspirin associated with phosphatidylcholine (PL2200) reduce GI ulcerations compared to standard low-dose aspirin in patients requiring LDA therapy?
Aspirin associated with phosphatidylcholine (PL2200) may offer a safer alternative to standard low-dose aspirin by significantly reducing gastrointestinal ulcerations.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tarnawski et al. (2018) conducted a review in Low-dose aspirin-induced GI ulcerations. Aspirin associated with phosphatidylcholine (PL2200) was evaluated on LDA-induced GI ulcerations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: